A Phase 1 Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in
patients with select blood cancers that have not responded to treatment with standard
therapies or who have relapsed after treatment. The study is designed to determine the
safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic
(affect of the drug on the body), immunogenicity (development of antibodies against the
drug), and preliminary anti-cancer effect of MGD024.
Patients will receive treatment with MGD024 in consecutive 28-day cycles for a study
treatment period of up to 12 cycles (approximately 1 year) or until treatment or study
discontinuation criteria are met. Response assessments will be performed after Cycle 1 and
then after every even numbered cycle starting with Cycle 2 until progression or study
treatment discontinuation. Patients will be checked for side effects throughout the study.